---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010873"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:40:28.801058+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam

## Summary
- Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.
- Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.
- Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.
- CEO Paul Goode highlights potentially transformative advancement in diabetes management.

## SEC filing metadata
- accession: 0001493152-25-010873
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/0001493152-25-010873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010873
- JSON: https://secwatch.observer/filing/0001493152-25-010873.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.